07:11 PM EST - Abattis Bioceuticals Corp. : Announced that it is has cancelled its previously announced non-brokered private placement for gross proceeds of up to $6 million, as described in the Company’s news release dated February 9, 2018, and is undertaking a new non-brokered private placement for gross proceeds of up to $8 million. The Company also announces that it has successfully closed the first tranche of the Offering through the issuance of 18,518,518 Units for gross proceeds of $5 million. Pursuant to the Offering, the Company will issue up to an aggregate of 29,629,629 units of the Company, including those issued pursuant to the First Tranche, at a price of $0.27 per Unit. Each Unit will consist of one common share of the Company and one common share purchase warrant, each Warrant entitling the holder to purchase one Common Share at an exercise price of $0.30 per Common Share for a period of twelve months from the closing date of the Offering. Abattis Bioceuticals Corp.
shares ATT:CNX are trading down 1 cent at the close at $0.27.
